---
title: "Panbela Therapeutics (PBLA.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/PBLA.US/norm.md"
symbol: "PBLA.US"
name: "Panbela Therapeutics"
parent: "https://longbridge.com/zh-CN/quote/PBLA.US.md"
datetime: "2026-03-13T17:05:33.742Z"
locales:
  - [en](https://longbridge.com/en/quote/PBLA.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PBLA.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PBLA.US/norm.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/PBLA.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/PBLA.US/norm.md)


# Panbela Therapeutics (PBLA.US) — 财务报表

## 利润表 (USD)

| 指标 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
| --- | --- | --- | --- | --- | --- |
| EPS | -1.48 | -1.47 | -2.28 | -65.82 | -53.74 |
| ROE | 199.67% | 415.24% | 721.38% | 1736.58% | -2701.51% |
| Revenue | - | - | - | - | - |
| Net income | -7.17M | -7.14M | -7.12M | -15.61M | -7.83M |
| Operating income | -7.17M | -8.10M | -6.73M | -7.04M | -7.85M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
| --- | --- | --- | --- | --- | --- |
| A&L | 5.17M | 9.41M | 10.53M | 11.80M | 10.63M |
| Leverage | -0.2845 | -0.8908 | -3.30 | -2.51 | -4.28 |
| BVPS | -3.74 | -2.18 | -0.6562 | -9.81 | -16.57 |
| Turnover | - | - | - | - | - |
| Cash & STI | 4.73M | 59000.00 | 262000.00 | 2.58M | 907000.00 |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | 1.67M | 4.13M | 3.93M | 2.62M | 4.29M |

## 现金流量表 (USD)

| 指标 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -2.12M | -981000.00 | -9.39M | -3.08M | -6.68M |
| Investing CF | 0.0000 | 775000.00 | - | 0.0000 | 400000.00 |
| Financing CF | 2.20M | 0.0000 | 7.08M | 4.75M | -19000.00 |
| Free CF | -3.05M | 2.79M | -6.94M | -380500.00 | -3.52M |
| OCF coverage | - | - | -939.20% | - | - |
| Repaid & issued | 2.20M | - | - | - | - |
| CapEx | - | - | - | - | - |